Related Experiment Video
Updated: Aug 14, 2026
08:54
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
LINAC-based single-isocenter stereotactic radiotherapy for multiple brain metastases
Hikaru Niitsu1,2, Yoshio Tamaki1,3, Yuichi Hiroshima1,2,4
1Department of Radiation Oncology, Ibaraki Prefectural Central Hospital, Ibaraki Cancer Center, Kasama, 309-1793, Japan.
Journal of Radiation Research
|August 12, 2026
Summary
The Elements Multiple Brain Mets System (mSRS/SRT) shows promise for treating multiple brain metastases, with a 12-month survival rate of 48.5%. Systemic therapy improved outcomes for both survival and local control in patients receiving mSRS/SRT.
Area of Science:
- Neurosurgery
- Radiation Oncology
- Medical Physics
Background:
- Stereotactic radiosurgery/radiotherapy (SRS/SRT) is increasingly used for multiple brain metastases.
- The Elements Multiple Brain Mets System (mSRS/SRT) utilizes dynamic conformal arc therapy with a single isocenter.
- Evaluating the clinical outcomes of the mSRS/SRT system is crucial for its adoption.
Purpose of the Study:
- To analyze the treatment outcomes of the Elements Multiple Brain Mets System (mSRS/SRT) for multiple brain metastases.
- To identify factors associated with overall survival, local control, and intracranial control.
- To assess the safety and adverse events associated with the mSRS/SRT system.
Main Methods:
- Retrospective analysis of 29 patients (130 lesions) treated with mSRS/SRT from December 2018 to March 2023.
- Dose prescription based on tumor size: single fraction (≤2 cm) or hypofractionated ( >2 cm).
- Median follow-up of 7.2 months, assessing overall survival, local recurrence, intracranial control, and adverse events.
Main Results:
- 12-month overall survival rate was 48.5%; systemic therapy post-mSRS/SRT correlated with improved survival.
- 12-month lesion-based local recurrence rate was 14.4%; larger tumors had poorer control, while systemic therapy improved it.
- 12-month intracranial control rate was 43.6%; non-lung primaries, more lesions, and pre-mSRS/SRT systemic therapy were linked to poorer control. Asymptomatic brain necrosis occurred in 9 patients.
Conclusions:
- The mSRS/SRT system demonstrates potential as a treatment option for multiple brain metastases.
- Systemic therapy plays a significant role in improving outcomes for patients treated with mSRS/SRT.
- Further research is warranted to fully establish the efficacy and long-term benefits of the mSRS/SRT system.
